Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 21;4(1):pkz085. doi: 10.1093/jncics/pkz085

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contactjournals.permissions@oup.com

PMC Copyright notice

Figure 4. — PROs for the TNBC population. A) EORTC QLQ-C30: global health status or quality of life (GHS/QoL) and functional scales; EORTC QLQ-BR23: functional scales. B) EORTC QLQ-C30: symptom scales; EORTC QLQ-BR23: symptom scales. Forest plot model of estimated difference (talazoparib and overall PCT) in overall change from baseline (repeated measures mixed-effect model) in PRO-evaluable population (P values are shown only if significant between-arm differences, P < .05, were observed). *The sample sizes for the “sexual enjoyment” functional scale were smaller vs other functional scales because patients were asked to respond to this question only if they responded that they were sexually active in a previous question. EORTC = European Organisation for Research and Treatment of Cancer; HR+ = hormone receptor-positive; HER2− = human epidermal growth factor receptor 2-negative; PCT = physician’s choice of chemotherapy treatment; PRO = patient-reported outcomes; QLQ-BR23 = Quality of Life Questionnaire-Breast Cancer Module; QLQ-C30 = Quality of Life Questionnaire-Core 30. ^†The sample sizes for the “upset by hair loss” symptom scale were smaller vs other symptom scales because patients were asked to respond to this question only if they responded to experiencing hair loss in a previous question. PRO-evaluable population defined as all patients who completed one or more PRO question at baseline and one or more PRO question postbaseline.